{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-074763","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2024-06-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.783129+00:00","generated_at":"2026-06-01T02:14:00.578962+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiniksa signs manufacturing agreement with Samsung Biologics for ARCALYST","bullets":["Wholly-owned subsidiary entered MSA and PSA with Samsung Biologics for ARCALYST (rilonacept) drug substance.","Kiniksa committed to purchase PPQ and pre-approval inspection batches; additional batches required in 2027-2031.","PSA continues until later of Dec 31, 2031 or service completion; MSA initial 10-year term with 2-year auto-renewals.","Agreement includes customary indemnification, IP protection, limitation of liability, and confidentiality provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-074763","json":"https://secwatch.observer/filing/0001104659-24-074763.json","markdown":"https://secwatch.observer/filing/0001104659-24-074763.md","text":"https://secwatch.observer/filing/0001104659-24-074763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924074763/0001104659-24-074763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924074763/tm2417478d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:14:00.578962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}